Tapentadol

Dual mechanism of action combining mu-opioid receptor agonism and norepinephrine reuptake inhibition characterizes tapentadol, a Schedule II centrally-acting analgesic prescribed for moderate to severe acute and chronic pain including diabetic peripheral neuropathy. Laboratory testing applications include pain management compliance monitoring, drugs of abuse screening, forensic toxicology investigations, postmortem toxicology, and clinical toxicology assessments, where tapentadol testing has become increasingly important as prescribing has grown and the drug is not detected by standard opiate immunoassays. UTAK’s Pain Management, Pain Management Plus, and SAMHSA CONFIRM panels contain tapentadol in lyophilized urine, whole blood, and oral fluid matrices at multiple concentration levels, supporting both immunoassay screening and confirmation methods. Stock and custom QC solutions can incorporate related analytes such as tramadol, oxycodone, hydrocodone, fentanyl, morphine, and other commonly monitored pain management drugs to address your laboratory’s comprehensive opioid and drugs of abuse testing requirements.